Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence 1Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer 1Pancreatic Neoplasms 1Lung Neoplasms 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer 1Advanced Solid Tumor 1Advanced Malignant Tumors 1

Interventions

Injections 12pembrolizumab 11Nivolumab 9Paclitaxel 8senaparib 7Docetaxel 7Cisplatin 6Capecitabine 6Gemcitabine 5toripalimab 4tislelizumab 4atezolizumab 4Ipilimumab 4Carboplatin 4Bevacizumab 4sintilimab 3Rifampin 3Oxaliplatin 3Itraconazole 3130-nm albumin-bound paclitaxel 3zimberelimab 2pertuzumab 2osimertinib 2ontuxizumab 2navoximod 2magrolimab 2fluzoparib 2famitinib 2durvalumab 2camrelizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Solid Tumor × SHR-1701 × Clear all
NCT04679038 2022-01-26

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
222 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡